Supplementary Table 1. Baseline Characteristics by Quintiles of Systolic and Diastolic Blood Pressures
|
|
|
- Kathleen Johns
- 5 years ago
- Views:
Transcription
1 Supplementary Data Supplementary Table 1. Baseline Characteristics by Quintiles of Systolic and Diastolic Blood Pressures Quintiles of Systolic Blood Pressure Quintiles of Diastolic Blood Pressure Q1 Q2 Q3 Q4 Q5 Q1 Q2 Q3 Q4 Q5 N= 7324 N= 7395 N= 7177 N= 5771 N= 6342 N= 5970 N= N= 2424 N= 6773 N= (12.1) Age, years (12.7) (12.0) (11.3) (10.9) (10.6) (12.6) (11.5) (11.6) (11.4) Female, n 3070 (42) 3214 (44) 3334 (47) 2862 (50) 3524 (56) 3087 (52) 5635 (49) 1163 (48) 3159 (47) 2960 (40) Body mass index, 29.6 (5.4) 30.5 (5.5) 30.4 (5.3) 30.5 (5.4) 29.9 (5.3) 28.7 (5.1) 29.6 (5.2) 29.9 (5.1) 30.9 (5.3) 31.6 (5.6) kg/m 2 HbA1c, % 7.3 (1.5) 7.3 (1.3) 7.3 (1.3) 7.3 (1.4) 7.4 (1.3) 7.2 (1.3) 7.3 (1.4) 7.3 (1.3) 7.4 (1.4) 7.4 (1.4) Systolic BP, mm Hg 123 (7) 137 (3) 146 (3) 156 (3) 174 (11) 135 (18) 142 (16) 147 (15) 150 (15) 159 (17) Diastolic BP, mm Hg 75 (8) 80 (7) 82 (8) 84 (8) 88 (10) 68 (5) 78 (2) 82 (1) 85 (1) 94 (5) Triglycerides, mm 2 (1.5) 2.0 (1.5) 2.1 (1.5) 2.1 (1.5) 2.0 (1.3) 1.8 (1.4) 2.0 (1.4) 2.1 (1.5) 2.1 (1.5) 2.3 (1.6) Total cholesterol, mm 5.2 (1.1) 5.3 (1.1) 5.4 (1.1) 5.5 (1.1) 5.6 (1.1) 5.2 (1.1) 5.3 (1.1) 5.4 (1.0) 5.5 (1.1) 5.6 (1.2) LDL cholesterol, mm 1.5 (1.0) 1.5 (0.9) 1.5 (0.9) 1.5 (0.9) 1.5 (0.8) 1.6 (0.9) 1.5 (0.9) 1.5 (0.9) 1.5 (0.9) 1.4 (0.9) HDL cholesterol, mm 3.2 (0.9) 3.2 (0.9) 3.3 (0.9) 3.3 (0.9) 3.4 (1.0) 3.1 (0.9) 3.2 (0.9) 3.3 (0.9) 3.3 (0.9) 3.4 (0.9) Creatinine, µm 80 (23) 82 (22) 82 (21) 84 (24) 86 (25) 84 (26) 83 (23) 82 (24) 82 (22) 83 (23) egfr, ml/min/ (20) 80 (19) 78 (19) 75 (19) 71 (19) 75 (20) 77 (19) 78 (19) 79 (19) 80 (19) m 2 Smoker, n 1,168 (23) 1,022 (19) 830 (16) 628 (15) 635 (15) 726 (18) 1,437 (18) 294 (16) 842 (17) 984 (19) Antihypertensive 1,838 (25) 2,624 (36) 3,078 (43) 2,808(49) 3,329 (53) 2,071 (35) 4,029 (35) 1,079 (45) 2,931 (43) 3,567 (49) drugs, n Alpha-blockers 21 (0) 28 (0) 43 (1) 45 (1) 46 (1) 34 (1) 50 (0) 13 (1) 36 (1) 50 (1) ARBs 399 (5) 621 (8) 733 (10) 614 (11) 750 (12) 478 (8) 886 (8) 221 (9) 639 (9) 893 (12) ACE-inhibitors 636 (9) 858 (12) 1,089 (15) 1,062(18) 1,337 (21) 709 (12) 1,273 (11) 373 (15) 1,123 (17) 1,504 (21) Calcium antagonists 438 (6) 745 (10) 922 (13) 844 (15) 981 (16) 670 (11) 1,172 (10) 320 (13) 854 (13) 914 (13) Thiazides 312 (4) 544 (7) 631 (9) 536 (9) 590 (9) 392 (7) 784 (7) 230 (10) 579 (9) 628 (9) Beta-blockers 1,001 (14) 1,400 (19) 1,511 (21) 1,395(24) 1,727 (27) 1,109 (19) 2,205 (19) 575 (24) 1,428 (21) 1,717 (23) Lipid-lowering drugs, 1,258 (17) 1,490 (20) 1,341 (19) 1,047(18) 843 (13) 1,155 (19) 2,017 (18) 485 (20) 1,166 (17) 1,156 (16) n Insulin, n 658 (9) 559 (8) 552 (8) 437 (8) 525 (8) 660 (11) 994 (9) 171 (7) 485 (7) 421 (6)
2 Oral glucose-lowering 2,420 (33) 2,561 (35) 2,451 (34) 2,048 (36) 2,263 (36) 1,883 (32) 3,945 (34) 836 (35) 2,437 (36) 2,642 (36) drugs, n Education Elementary school 2,442 (36) 2,776 (41) 2,831 (44) 2,408(47) 2,772 (53) 2,320 (45) 4,585 (45) 979 (44) 2,596 (42) 2,749 (41) Secondary school 2,225 (33) 2,120 (31) 2,035 (31) 1,545(30) 1,402 (27) 1,510 (30) 3,012 (30) 663 (30) 1,970 (32) 2,172 (32) College or graduate exam 2,077 (31) 1,891 (28) 1,641 (25) 1,179 (23) 1,024 (20) 1,295 (25) 2,589 (25) 570 (26) 1,582 (26) 1,776 (27) Marital status Married 3,708 (52) 3,943 (54) 3,808 (54) 2,968(52) 3,174 (51) 2,982 (51) 6,058 (54) 1,302 (54) 3,533 (53) 3,726 (52) Divorced 1,344 (19) 1,212 (17) 1,171 (17) 943 (17) 906 (14) 924 (16) 1,818 (16) 383 (16) 1,122 (17) 1,329 (18) Unmarried 1,425 (20) 1,239 (17) 1,004 (14) 760 (13) 714 (11) 760 (13) 1,591 (14) 342 (14) 1,109 (17) 1,340 (19) Widow/widower 688 (10) 889 (12) 1,098 (16) 1,026 (18) 1,450 (23) 1,169 (20) 1,843 (16) 375 (16) 926 (14) 838 (12) Data are means (standard deviations) or numbers of individuals (percent). BP, blood pressure; LDL, low-density lipoprotein; HDL, high-density lipoprotein; egfr, estimated glomerular filtration rate; ARBs, angiotensin receptor-blockers; ACE, angiotensinconverting enzyme. Quintile limits for systolic blood pressure were <130; ; ; ; and >160 mm Hg; and those for diastolic blood pressure were <73; 73-78; 78-81; 81-87; and >87 mm Hg.
3 Supplementary Table 2. Relations of Quintiles of Systolic and Diastolic Blood Pressures to Risk of Cardiovascular Events and Mortality No antihypertensive Models A Models B Models C Antihypertensive Antihypertensive No antihypertensive No antihypertensive Antihypertensive Risk of Cardiovascular Events Systolic blood pressure Quintile 1 (<130 mm Hg) Quintile 2 ( mm Hg) 1.20 ( ) 0.89 ( ) 0.98 ( ) 0.87 ( ) 1.24 ( ) 0.94 ( ) Quintile 3 ( mm Hg) 1.38 ( ) 0.87 ( ) 0.96 ( ) 0.82 ( ) 1.35 ( ) 1.03 ( ) Quintile 4 ( mm Hg) 1.91 ( ) 1.08 ( ) 1.17 ( ) 0.93 ( ) 1.29 ( ) 0.98 ( ) Quintile 5 (>160 mm Hg) 2.59 ( ) 1.50 ( ) 1.28 ( ) 1.15 ( ) 1.79 ( ) 1.37 ( ) Diastolic blood pressure Quintile 1 (<73 mm Hg) Quintile 2 (73-78 mm Hg) 0.79 ( ) 0.79 ( ) 0.92 ( ) 0.92 ( ) 1.65 ( ) 1.00 ( ) Quintile 3 (78-81 mm Hg) 0.79 ( ) 0.85 ( ) 0.94 ( ) 1.05 ( ) 1.11 ( ) 0.89 ( ) Quintile 4 (81-87 mm Hg) 0.72 ( ) 0.70 ( ) 0.94 ( ) 0.99 ( ) 1.36 ( ) 0.93 ( ) Quintile 5 (>87 mm Hg) 0.89 ( ) 0.76 ( ) 1.23 ( ) 1.29 ( ) 2.01 ( ) 1.24 ( ) Risk of Mortality Systolic blood pressure Quintile 1 (<130 mm Hg) Quintile 2 ( mm Hg) 0.97 ( ) 0.71 ( ) 0.77 ( ) 0.71 ( ) 1.00 ( ) 0.75 ( ) Quintile 3 ( mm Hg) 0.93 ( ) 0.59 ( ) 0.62 ( ) 0.56 ( ) 1.02 ( ) 0.63 ( ) Quintile 4 ( mm Hg) 1.30 ( ) 0.80 ( ) 0.75 ( ) 0.69 ( ) 0.90 ( ) 0.65 ( ) Quintile 5 (>160 mm Hg) 1.63 ( ) 0.95 ( ) 0.72 ( ) 0.71 ( ) 0.90 ( ) 0.72 ( ) Diastolic blood pressure Quintile 1 (<73 mm Hg) Quintile 2 (73-78 mm Hg) 0.64 ( ) 0.71 ( ) 0.76 ( ) 0.84 ( ) 0.97 ( ) 0.78 ( ) Quintile 3 (78-81 mm Hg) 0.69 ( ) 0.76 ( ) 0.83 ( ) 0.95 ( ) 0.77 ( ) 0.77 ( ) Quintile 4 (81-87 mm Hg) 0.54 ( ) 0.53 ( ) 0.73 ( ) 0.78 ( ) 0.94 ( ) 0.69 ( ) Quintile 5 (>87 mm Hg) 0.63 ( ) 0.57 ( ) 0.90 ( ) 1.01 ( ) 0.82 ( ) 0.93 ( )
4 Data are Cox proportional hazard ratios (95% confidence intervals). Model A, unadjusted; model B, adjusting for gender and age; model C, adjusting for gender, age, smoking, education and body mass index. Supplementary Table 3. Systolic and Diastolic Blood Pressures at Lowest Risk of Cardiovascular Events and Mortality Starting Follow-Up Two Years After Baseline Date Risk of Cardiovascular Events No antihypertensive Antihypertensive No antihypertensive Risk of Mortality Antihypertensive Systolic blood pressure at lowest risk Diastolic blood pressure at lowest risk Data are systolic and diastolic blood pressures corresponding to lowest risk of cardiovascular events and mortality from multivariableregression spline models B (adjusting for age and gender; stratified by antihypertensive treatment use) starting follow-up two years after baseline date.
5 Supplementary Figure 1. Distributions of Systolic and Diastolic Blood Pressures
6 Supplementary Figure 2. Cumulative Incidence of Cardiovascular Events and Mortality by Quintiles of Blood Pressure Levels A B C D Cumulative incidence of cardiovascular events (panels A & B) and mortality (panels C & D) by quintiles of systolic blood pressure (panels A & C) and diastolic blood pressure (panels B & D), by years of follow-up. All log-rank p-values< Quintile blood pressure limits as in Supplementary Table 1.
7 Supplementary Figure 3. Natures of Associations of Blood Pressure Levels With Risk of Cardiovascular Events by Gender A B C D Risk of cardiovascular events by systolic (panels A & B) and diastolic (panels C & D) blood pressures in untreated (A & C) and antihypertensive drug treated (B & D) persons (pink lines, men; blue lines, women; shaded fields, 95% confidence intervals). Multiplicative interaction terms between gender and systolic blood pressure in untreated p=0.97 and antihypertensive drug treated p=0.34; and between gender and diastolic blood pressure in untreated p=0.38 and treated p=0.01.
8 Supplementary Figure 4. Natures of Associations of Blood Pressure Levels With Risk of Cardiovascular Events by Age A B C D Risk of cardiovascular events by systolic (panels A & B) and diastolic (panels C & D) blood pressures in untreated (A & C) and antihypertensive drug treated (B & D) persons (pink lines, above median age; blue lines, below median age; shaded fields, 95% confidence intervals). Multiplicative interaction terms between age and systolic blood pressure in untreated p< and antihypertensive drug treated p<0.0001; and between age and diastolic blood pressure in untreated p=0.09 and treated p=0.30.
9 Supplementary Figure 5. Natures of Associations of Blood Pressure Levels With Risk of Cardiovascular Events by Body Mass Index A B C D Risk of cardiovascular events by systolic (panels A & B) and diastolic (panels C & D) blood pressures in untreated (A & C) and antihypertensive drug treated (B & D) persons (pink lines, above median body mass index; blue lines, below median body mass index; shaded fields, 95% confidence intervals). Multiplicative interaction terms between body mass index and systolic blood pressure in untreated p=0.98 and antihypertensive drug treated p=0.03; and between body mass index and diastolic blood pressure in untreated p=0.99 and treated p=0.06.
10 Supplementary Figure 6. Natures of Associations of Blood Pressure Levels With Risk of Cardiovascular Events by HbA1c A B C D Risk of cardiovascular events by systolic (panels A & B) and diastolic (panels C & D) blood pressures in untreated (A & C) and antihypertensive drug treated (B & D) persons (pink lines, above median HbA1c; blue lines, below median HbA1c; shaded fields, 95% confidence intervals). Multiplicative interaction terms between HbA1c and systolic blood pressure in untreated p=0.90 and antihypertensive drug treated 0.35; and between HbA1c and diastolic blood pressure in untreated p=0.40 and treated p=0.92.
11 Supplementary Figure 7. Natures of Associations of Blood Pressure Levels With Risk of Cardiovascular Events by egfr A B C D Risk of cardiovascular events by systolic (panels A & B) and diastolic (panels C & D) blood pressures in untreated (A & C) and antihypertensive drug treated (B & D) persons (pink lines, above median egfr; blue lines, below median egfr; shaded fields, 95% confidence intervals). Multiplicative interaction terms between egfr and systolic blood pressure in untreated p< and antihypertensive drug treated p=0.0009; and between egfr and diastolic blood pressure in untreated p=0.75 and treated p=
12 Supplementary Figure 8. Natures of Associations of Blood Pressure Levels With Risk of Cardiovascular Events by Antidiabetic Treatment (no treatment vs. oral hypoglycemic treatment vs. insulin treatment) Risk of cardiovascular events by systolic (panels A & B) and diastolic (panels C & D) blood pressures in untreated (A & C) and antihypertensive drug treated (B & D) persons (pink lines, oral hypoglycemictherapy; blue lines, no antidiabetic drugs; green lines, insulin therapy; shaded fields, 95% confidence intervals). Multiplicative interaction terms between antidiabetic and systolic blood pressure in antihypertensive drug untreated p=0.38 and treated p=0.30; and between antidiabetic and diastolic blood pressure in antihypertensive drug untreated p=0.009 and treated p=0.39.
egfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
Supplementary Online Content
Supplementary Online Content Afkarian M, Zelnick L, Hall YN, et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014. JAMA. doi:10.1001/jama.2016.10924 emethods efigure
(n=6279). Continuous variables are reported as mean with 95% confidence interval and T1 T2 T3. Number of subjects
Table 1. Distribution of baseline characteristics across tertiles of OPG adjusted for age and sex (n=6279). Continuous variables are reported as mean with 95% confidence interval and categorical values
SITA 100 mg (n = 378)
Supplementary Table 1. Summary of Sulfonylurea Background Therapy at Baseline and During the Treatment Period. Sulfonylurea at baseline, n (%) SITA 100 mg (n = 378) CANA 300 mg (n = 377) Total (N = 755)
Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors.
Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors. Appendix to: Banks E, Crouch SR, Korda RJ, et al. Absolute risk of cardiovascular
Online Appendix (JACC )
Beta blockers in Heart Failure Collaborative Group Online Appendix (JACC013117-0413) Heart rate, heart rhythm and prognostic effect of beta-blockers in heart failure: individual-patient data meta-analysis
Module 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension
Module 2 Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension 1 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored,
GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS
GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS Table of Contents List of authors pag 2 Supplemental figure I pag 3 Supplemental figure II pag 4 Supplemental
Supplementary Online Content
Supplementary Online Content Xu X, Qin X, Li Y, et al. Efficacy of folic acid therapy on the progression of chronic kidney disease: the Renal Substudy of the China Stroke Primary Prevention Trial. JAMA
Supplementary Table 1. Patient demographics and baseline characteristics (treated patients).
Supplementary Table 1. Patient demographics and baseline characteristics (treated patients). Placebo (n=188) 10 mg (n=186) 25 mg (n=189) Total (n=563) Gender, n (%) Male 75 (40) 97 (52) 84 (44) 256 (45)
Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic
Supplementary Information The title of the manuscript Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic stroke Xin-Wei He 1, Wei-Ling Li 1, Cai Li
Magnetic resonance imaging, image analysis:visual scoring of white matter
Supplemental method ULSAM Magnetic resonance imaging, image analysis:visual scoring of white matter hyperintensities (WMHI) was performed by a neuroradiologist using a PACS system blinded of baseline data.
Supplementary Online Content
Supplementary Online Content Pedersen SB, Langsted A, Nordestgaard BG. Nonfasting mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis. JAMA Intern Med. Published online November 7, 2016.
Supplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
Supplementary Information for: Predictors of chronic kidney disease in type 1 diabetes: a longitudinal study from the AMD Annals initiative.
Supplementary Information for: Predictors of chronic kidney disease in type 1 diabetes: a longitudinal study from the AMD Annals initiative. Authors: Pamela Piscitelli 1, Francesca Viazzi 2 ; Paola Fioretto
Supplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Rawshani Aidin, Rawshani Araz, Franzén S, et al. Risk factors,
Know Your Number Aggregate Report Single Analysis Compared to National Averages
Know Your Number Aggregate Report Single Analysis Compared to National s Client: Study Population: 2242 Population: 3,000 Date Range: 04/20/07-08/08/07 Version of Report: V6.2 Page 2 Study Population Demographics
Figure S1. Comparison of fasting plasma lipoprotein levels between males (n=108) and females (n=130). Box plots represent the quartiles distribution
Figure S1. Comparison of fasting plasma lipoprotein levels between males (n=108) and females (n=130). Box plots represent the quartiles distribution of A: total cholesterol (TC); B: low-density lipoprotein
Supplementary Table 1. Criteria for selection of normal control individuals among healthy volunteers
Supplementary Table 1. Criteria for selection of normal control individuals among healthy volunteers Medical parameters Cut-off values BMI (kg/m 2 ) 25.0 Waist (cm) (Men and Women) (Men) 85, (Women) 90
Resistant hypertension (RH), that is, blood pressure (BP)
Resistant Hypertension, Time-Updated Blood Pressure Values and Renal Outcome in Type 2 Diabetes Mellitus Francesca Viazzi, MD; Pamela Piscitelli, MD; Antonio Ceriello, MD; Paola Fioretto, MD; Carlo Giorda,
Supplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Serra AL, Poster D, Kistler AD, et al. Sirolimus and kidney
Lowering blood pressure (BP) in patients with type 2
Average Clinician-Measured Blood Pressures and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Ischemic Heart Disease in the EXAMINE Trial William B. White, MD; Fatima Jalil, MD;
1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria
1. Albuminuria an early sign of glomerular damage and renal disease albuminuria Cardio-renal continuum REGRESS Target organ damage Asymptomatic CKD New risk factors Atherosclerosis Target organ damage
GATEWAY Trial. Bariatric Surgery versus Conventional Medical Treatment in Obese Patients with Hypertension
GATEWAY Trial Bariatric Surgery versus Conventional Medical Treatment in Obese Patients with Hypertension Carlos Aurelio Schiavon, MD, FACS On behalf of the GATEWAY Executive Committee and Investigators
Antihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
New Hypertension Guideline Recommendations for Adults July 7, :45-9:30am
Advances in Cardiovascular Disease 30 th Annual Convention and Reunion UERM-CMAA, Inc. Annual Convention and Scientific Meeting July 5-8, 2018 New Hypertension Guideline Recommendations for Adults July
Effects of Lowering LDL Cholesterol on Progression of Kidney Disease
Effects of Lowering LDL Cholesterol on Progression of Kidney Disease Richard Haynes, David Lewis, Jonathan Emberson, Christina Reith, Lawrence Agodoa, Alan Cass, Jonathan C. Craig, Dick de Zeeuw, Bo Feldt-Rasmussen,
5.2 Key priorities for implementation
5.2 Key priorities for implementation From the full set of recommendations, the GDG selected ten key priorities for implementation. The criteria used for selecting these recommendations are listed in detail
Risk Assessment of developing type 2 diabetes mellitus in patient on antihypertensive medication
41 Research Article Risk Assessment of developing type 2 diabetes mellitus in patient on antihypertensive medication Amarjeet Singh*, Sudeep bhardwaj, Ashutosh aggarwal Department of Pharmacology, Seth
Supplementary Online Content
Supplementary Online Content Clair C, Rigotti NA, Porneala B, et al. Association of smoking cessation and weight change with cardiovascular disease among people with and without diabetes. JAMA. doi:10.1001/jama.2013.1644.
SUPPLEMENTARY DATA. Supplementary Table 1. Baseline Patient Characteristics
Supplementary Table 1. Baseline Patient Characteristics Normally distributed data are presented as mean (±SD), data that were not of a normal distribution are presented as median (ICR). The baseline characteristics
Supplementary table 1 Demographic and clinical characteristics of participants by paraoxonase-1 (PON-1) gene polymorphisms
Supplementary table 1 Demographic and clinical characteristics of participants by paraoxonase-1 (PON-1) gene polymorphisms QQ QR/RR n = 36 n = 80 Men (%) 20 (55) 54 (67) 0.216 Age (years) 57 ± 10 56 ±
Supplementary Material. Serum Chloride is an Independent Predictor of Mortality in Hypertensive Patients
Supplementary Material Serum Chloride is an Independent Predictor of Mortality in Hypertensive Patients Linsay McCallum,* Panniyammakal Jeemon,* Claire E Hastie, Rajan K Patel, Catherine Williamson, Adyani
Cardiovascular Diabetology. Open Access ORIGINAL INVESTIGATION. C. R. L. Cardoso 1, N. C. Leite 1, C. B. M. Moram 2 and G. F.
https://doi.org/10.1186/s12933-018-0677-0 Cardiovascular Diabetology ORIGINAL INVESTIGATION Open Access Long term visit to visit glycemic variability as predictor of micro and macrovascular complications
Deprivation Study. The Freiburg Study
The Freiburg Study Deprivation Study Free Radicals Inflammation (hs-crp) Blood Pressure (Systolic, Diastolic) Blood Lipids (Cholesterol, Triglycerides) Energy Utilization (Heart Rate) Sugar Metabolism
Data Analysis Plan for assessing clinical efficacy and safety of ER niacin/laropiprant in the HPS2-THRIVE trial
Data Analysis Plan for assessing clinical efficacy and safety of ER niacin/laropiprant in the HPS2-THRIVE trial 1 Background This Data Analysis Plan describes the strategy, rationale and statistical methods
Supplemental Table S2: Subgroup analysis for IL-6 with BMI in 3 groups
Supplemental Table S1: Unadjusted and Adjusted Hazard Ratios for Diabetes Associated with Baseline Factors Considered in Model 3 SMART Participants Only Unadjusted Adjusted* Baseline p-value p-value Covariate
VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005
VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005 1 Any adult in the health care system 2 Obtain blood pressure (BP) (Reliable,
Supplementary Online Content
Supplementary Online Content Larsen JR, Vedtofte L, Jakobsen MSL, et al. Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia
Hypertension and Cardiovascular Disease
Hypertension and Cardiovascular Disease Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic,
Delacroix et al Renal effects of renal denervation Supplementary Figure 1: Changes in Ambulatory Blood Pressures and Heart Rate
Supplementary Figure 1: Changes in Ambulatory Blood Pressures and Heart Rate Supplementary Table 1: Ranking each patient based on the number of measurements showing a numerical improvement. Rank at each
SUPPLEMENTARY DATA. Supplementary Figure S1. Cohort definition flow chart.
Supplementary Figure S1. Cohort definition flow chart. Supplementary Table S1. Baseline characteristics of study population grouped according to having developed incident CKD during the follow-up or not
Update on Current Trends in Hypertension Management
Friday General Session Update on Current Trends in Hypertension Management Shawna Nesbitt, MD Associate Dean, Minority Student Affairs Associate Professor, Department of Internal Medicine Office of Student
Supplementary Online Content
Supplementary Online Content McEvoy JW, Chen Y, Ndumele CE, et al. Six-year change in high-sensitivity cardiac troponin T and risk of subsequent coronary heart disease, heart failure, and death. JAMA Cardiol.
Table 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use
Table 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use Baseline characteristics Users (n = 28) Non-users (n = 32) P value Age (years) 67.8 (9.4) 68.4 (8.5)
Composite Performance Report
Composite Performance Report 10 9 91% 8 7 65% 68% 65% 6 56% 5 4 3 2 44% 37% 48% 31% 19% 29% 1 6% Key: Report Measure Name Cohort Target Cohort Definition Formula 1 Control Blood Pressure All patients who
What s New in Bariatric Surgery?
Bariatric Surgery: Update for the General Surgeon What s New in Bariatric Surgery? 2,000 B.C. 2,000 A.D. 1. America keeps getting fatter without an end in sight. 2. Bariatric surgery is not just about
Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
JNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults
JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation
Hypertension and obesity. Dr Wilson Sugut Moi teaching and referral hospital
Hypertension and obesity Dr Wilson Sugut Moi teaching and referral hospital No conflict of interests to declare Obesity Definition: excessive weight that may impair health BMI Categories Underweight BMI
Effects of Bariatric Surgery in Obese Patients with Hypertension The GATEWAY Randomized Trial
Effects of Bariatric Surgery in Obese Patients with Hypertension The GATEWAY Randomized Trial Carlos Aurelio Schiavon, MD, FACS On behalf of the GATEWAY Executive Committee and Investigators DISCLOSURE
Clinical Recommendations: Patients with Periodontitis
The American Journal of Cardiology and Journal of Periodontology Editors' Consensus: Periodontitis and Atherosclerotic Cardiovascular Disease. Friedewald VE, Kornman KS, Beck JD, et al. J Periodontol 2009;
Supplemental table 1. Dietary sources of protein among 2441 men from the Kuopio Ischaemic Heart Disease Risk Factor Study MEAT DAIRY OTHER ANIMAL
ONLINE DATA SUPPLEMENT 1 SUPPLEMENTAL MATERIAL Pork Bacon Turkey Kidney Cream Cottage cheese Mutton and lamb Game (elk, reindeer) Supplemental table 1. Dietary sources of protein among 2441 men from the
Cardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003
Authorized By: Medical Management Guideline Committee Approval Date: 12/13/01 Revision Date: 12/11/03 Beta-Blockers Nitrates Calcium Channel Blockers MEDICATIONS Indicated in post-mi, unstable angina,
Clinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
Normal Fasting Plasma Glucose and Risk of Type 2 Diabetes Diagnosis
CLINICAL RESEARCH STUDY Normal Fasting Plasma Glucose and Risk of Type 2 Diabetes Diagnosis Gregory A. Nichols, PhD, Teresa A. Hillier, MD, MS, Jonathan B. Brown, PhD, MPP Center for Health Research, Kaiser
Val-MARC: Valsartan-Managing Blood Pressure Aggressively and Evaluating Reductions in hs-crp
Página 1 de 5 Return to Medscape coverage of: American Society of Hypertension 21st Annual Scientific Meeting and Exposition Val-MARC: Valsartan-Managing Blood Pressure Aggressively and Evaluating Reductions
The role of physical activity in the prevention and management of hypertension and obesity
The 1 st World Congress on Controversies in Obesity, Diabetes and Hypertension (CODHy) Berlin, October 26-29 2005 The role of physical activity in the prevention and management of hypertension and obesity
300 Biomed Environ Sci, 2018; 31(4):
300 Biomed Environ Sci, 2018; 31(4): 300-305 Letter to the Editor Combined Influence of Insulin Resistance and Inflammatory Biomarkers on Type 2 Diabetes: A Population-based Prospective Cohort Study of
Supplementary Online Content
Supplementary Online Content Nikolova AP, Hitzeman TC, Baum R, et al. Association of a novel diagnostic biomarker, the plasma cardiac bridging integrator 1 score, with heart failure with preserved ejection
Is there a mechanism of interaction between hypertension and dyslipidaemia?
Is there a mechanism of interaction between hypertension and dyslipidaemia? Neil R Poulter International Centre for Circulatory Health NHLI, Imperial College London Daegu, Korea April 2005 Observational
Supplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Solomon SD, Uno H, Lewis EF, et al. Erythropoietic response
Effects of Bariatric Surgery in Obese Patients with Hypertension The GATEWAY Randomized Trial
Effects of Bariatric Surgery in Obese Patients with Hypertension The GATEWAY Randomized Trial Carlos Aurelio Schiavon, MD, FACS On behalf of the GATEWAY Executive Committee and Investigators DISCLOSURE
Diabetes and Hypertension
Diabetes and Hypertension M.Nakhjvani,M.D Tehran University of Medical Sciences 20-8-96 Hypertension Common DM comorbidity Prevalence depends on diabetes type, age, BMI, ethnicity Major risk factor for
Guidelines to assist General Practitioners in the Management of Type 2 Diabetes. April 2010
Guidelines to assist General Practitioners in the Management of Type 2 Diabetes April 2010 Foreword The guidelines were devised by the Diabetes Day Centre in Beaumont Hospital in consultation with a number
Know Your Numbers Blood Pressure Cholesterol Blood Sugar
Know Your Numbers Blood Pressure Cholesterol Blood Sugar 2015 Wellness Warriors Sponsored by: Wayne State University Presented by: Debbie Cavender, RDN STRATEGIC WELLNESS, LLC The information in this presentation
Hypoinsulinemia is strongly associated with coronary artery calcification (CAC) assessed by multislice computed tomography
Hypoinsulinemia is strongly associated with coronary artery calcification (CAC) assessed by multislice computed tomography Yohei Oda 1, Muhei Tanaka 2, Michiaki Fukui 2, Sei Tsunoda 1, Satoshi Akabame
Triglyceride and HDL-C Dyslipidemia and Risks of Coronary Heart Disease and Ischemic Stroke by Glycemic Dysregulation Status: The Strong Heart Study
1/5 Triglyceride and HDL-C Dyslipidemia and Risks of Coronary Heart Disease and Ischemic Stroke by Glycemic Dysregulation Status: The Strong Heart Study Jennifer S. Lee, Po-Yin Chang, Ying Zhang, Jorge
How Low Do We Go? Update on Hypertension
How Low Do We Go? Update on Beth L. Abramson, MD, FRCPC, FACC As presented at the University of Toronto s Saturday at the University Session (September 2003) Arecent World Health Organization report states
Supplementary Online Content
Supplementary Online Content Ebbing M, Bønaa KH, Nygård O, et al. Cancer incidence and mortality after treatment with folic acid and vitamin B 1. JAMA. 9;3(19):119-1. etable 1. Circulating Levels of B
Implementation of glm-boosting with R Package mboost
RSNA, 2017 10.1148/radiol.2017161228 Appendix E1 Implementation of glm-boosting with R Package mboost We used the function glmboost of the package mboost implemented in R (R Package for Statistical Computing).
hypertension Head of prevention and control of CVD disease office Ministry of heath
hypertension t. Samavat MD,Cadiologist,MPH Head of prevention and control of CVD disease office Ministry of heath RECOMMENDATIONS FOR HYPERTENSION DIAGNOSIS, ASSESSMENT, AND TREATMENT Definition of hypertension
University of Padova, Padua, Italy, and HARVEST Study Group, Italy
University of Padova, Padua, Italy, and HARVEST Study Group, Italy ISOLATED SYSTOLIC HYPERTENSION IN THE YOUNG DOES NOT IMPLY AN INCREASED RISK OF FUTURE HYPERTENSION NEEDING TREATMENT Mos L, Saladini
The Seventh Report of the Joint National Commission
The Effect of a Lower Target Blood Pressure on the Progression of Kidney Disease: Long-Term Follow-up of the Modification of Diet in Renal Disease Study Mark J. Sarnak, MD; Tom Greene, PhD; Xuelei Wang,
ALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic
1 U.S. Department of Health and Human Services National Institutes of Health Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker
Application of the Diabetes Algorithm to a Patient
Application of the Diabetes Algorithm to a Patient Apply knowledge gained from this activity to improve disease management and outcomes for patients with T2DM and obesity Note: The cases in this deck represent
SUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL Supplemental Table 1. Distribution of Participants Characteristics by Treatment Group at Baseline - The Vitamin D and calcium (CaD) Trial of the Women s Health Initiative (WHI) Study,
To reduce the risk of cardiovascular disease and diabetes among Oklahoma state employees.
E Nancy A. Haller, MPH, CHES, Manager, State Wellness Program M PLOYEES To reduce the risk of cardiovascular disease and diabetes among Oklahoma state employees. To suspend or decrease the rising costs
Bariatric Surgery versus Intensive Medical Therapy for Diabetes 3-Year Outcomes
The new england journal of medicine original article Bariatric Surgery versus Intensive Medical for Diabetes 3-Year Outcomes Philip R. Schauer, M.D., Deepak L. Bhatt, M.D., M.P.H., John P. Kirwan, Ph.D.,
Swindon Diabetes Guidelines: Management of Chronic Kidney Disease Associated with Diabetes Mellitus
Swindon Diabetes Guidelines: Management of Chronic Kidney Disease Associated with Diabetes Mellitus 1 Contents Executive Summary... 3 How to Screen for Diabetic Nephropathy... 4 What to Measure... 4 Frequency
Metformin should be considered in all patients with type 2 diabetes unless contra-indicated
November 2001 N P S National Prescribing Service Limited PPR fifteen Prescribing Practice Review PPR Managing type 2 diabetes For General Practice Key messages Metformin should be considered in all patients
DISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.
JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I
Indiana Medicaid Drug Utilization Review Board Newsletter
Indiana Medicaid Drug Utilization Review Board Newsletter Volume 12 Issue 4 October 2009 Indiana Medicaid DUR Board Room W382 Indiana State Government Center, South 402 West Washington Street Indianapolis,
Methods. Background and Objectives STRADIVARIUS
STRADIVARIUS Effect of on Progression of Atherosclerosis in Patients with Abdominal Obesity and Coronary Artery Disease Steven E. Nissen MD Stephen J. Nicholls MBBS PhD, Kathy Wolski MPH, Josep Rodés-Cabau
Multiple Factors Should Be Considered When Setting a Glycemic Goal
Multiple Facts Should Be Considered When Setting a Glycemic Goal Patient attitude and expected treatment effts Risks potentially associated with hypoglycemia, other adverse events Disease duration Me stringent
Hiroyuki Daikuhara 1, Fumi Kikuchi 2 and Toshihiko Ishida 2. Introduction. Original Article
447310DVR9410.1177/1479164112447310Daikuhara et al.diabetes and Vascular Disease Research 2012 Original Article The combination of OLmesartan and a CAlcium channel blocker (azelnidipine) or candesartan
CHAPTER 5 RENAL TRANSPLANTATION. Editor: Dr Rosnawati Yahya
CHAPTER 5 Editor: Dr Rosnawati Yahya Expert Panels: Dr Rosnawati Yahya Dr Ng Kok Peng Dr Suryati Binti Yakaob Dr Mohd Zaimi Abd Wahab Dr Yee Seow Ying Dr Wong Hin Seng Contents 5. Stock and Flow of Renal
Scoring Life Insurance Applicants Laboratory Results, Blood Pressure and Build to Predict All-Cause Mortality Risk
Copyright E 2012 Journal of Insurance Medicine J Insur Med 2012;43:169 177 MORTALITY Scoring Life Insurance Applicants Laboratory Results, Blood Pressure and Build to Predict All-Cause Mortality Risk Michael
Clinical cases with Coversyl 10 mg
Clinical cases Coversyl 10 mg For upgraded benefits in hypertension A Editorial This brochure, Clinical cases Coversyl 10 mg for upgraded benefits in hypertension, illustrates a variety of hypertensive
Depok-Indonesia STEPS Survey 2003
The STEPS survey of chronic disease risk factors in Indonesia/Depok was carried out from February 2003 to March 2003. Indonesia/Depok carried out Step 1, Step 2 and Step 3. Socio demographic and behavioural
Coronary Heart Disease. Relation Between Red Blood Cell Distribution Width and Cardiovascular Event Rate in People With Coronary Disease
Coronary Heart Disease Relation Between Red Blood Cell Distribution Width and Cardiovascular Event Rate in People With Coronary Disease Marcello Tonelli, MD, SM; Frank Sacks, MD; Malcolm Arnold, MD; Lemuel
Metabolic Syndrome and Chronic Kidney Disease
Metabolic Syndrome and Chronic Kidney Disease Definition of Metabolic Syndrome National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Abdominal obesity, defined as a waist circumference
SCIENTIFIC STUDY REPORT
PAGE 1 18-NOV-2016 SCIENTIFIC STUDY REPORT Study Title: Real-Life Effectiveness and Care Patterns of Diabetes Management The RECAP-DM Study 1 EXECUTIVE SUMMARY Introduction: Despite the well-established
Long-Term Care Updates
Long-Term Care Updates January 2016 By Yunuo (Enora) Wu, PharmD Chronic kidney disease (CKD) is defined as kidney damage (including structural or functional abnormalities) or glomerular filtration rate
Background- Methods and Results- Conclusion-
Patterns of Use of Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Among Patients With Acute Myocardial Infarction in China From 2001 to 2011: China PEACE Retrospective AMI Study
Clinical Practice Guideline Key Points
Clinical Practice Guideline Key Points Clinical Practice Guideline 2008 Key Points Diabetes Mellitus Provided by: Highmark Endocrinology Clinical Quality Improvement Committee In accordance with Highmark
New Hypertension Guidelines. Kofi Osei, MD
New Hypertension Guidelines Kofi Osei, MD None Disclosures Objectives The new blood pressure definitions and cardiovascular risk The role to time and location in the diagnosis of hypertension Apply evidence-based
RISK FACTORS OR COMPLICATIONS AND RECOMMENDED TREATMENT GOALS AND FREQUENCY OF EVALUATION FOR ADULTS WITH DIABETES
RISK FACTORS OR COMPLICATIONS AND RECOMMENDED TREATMENT GOALS AND FREQUENCY OF EVALUATION FOR ADULTS WITH DIABETES Risk Factors or Complications Glycemic Control Fasting & Capillary Plasma Glucose Anti-platelet
Hypertension Clinical case scenarios for primary care
Hypertension Clinical case scenarios for primary care Implementing NICE guidance August 2011 NICE clinical guideline 127 What this presentation covers Five clinical case scenarios, including: presentation